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Abstract
Study objective-The aim was to examine whether a high intake of aluminium containing antacids is a risk for Alzheimer's disease.
Design-The mortality from dementia (1970-87), coded from death certificates as underlying or contributory cause of death, was compared with national rates in a cohort of patients who had surgery for gastroduodenal ulcer disease between 1911 and 1978.
Setting-Patient data were obtained from patient records from major hospitals in western Norway.
Participants-4179 patients were identified who met the study criteria, which included having had a documented stomach operation, having a reliably identifiable personal number, and being alive on Jan 1, 1970 .
Measurements and main results-The standardised mortality ratio for dementia was 1-10 (95% CI 0-85-1P40, n=64) for all patients, while for patients operated on in the period 1967-78 it was 1-25 (95% CI 0-66-2-13, n = 13).
Conclusions-As the majority of patients operated on after 1963 have probably been heavy consumers of aluminium containing antacids, the study provides meager evidence that a high intake of aluminium is an important risk factor for Alzheimer's disease, the ICD-8 (1970-85) , and 219 according to ICD-9 (1986-87 Among the patients operated on in the period 1967-78, the SMR for those operated on after the age of 70 (seven dementia cases) was 1-50 (95o% CI 0-60-3-09); for those operated on before the age of 70 (six cases), the SMR was 1-04 (95% CI 0 38-
2-28).
For all deaths coded with dementia in Norway in the period 1974-83 the mean age at death was 81-7 years for men (n = 5642) and 83-5 for women (n = 9085). In the cohort, the corresponding numbers were 81-8 years for men and 83-7 for women ( In conclusion, although it should be noted that the SMRS in the three most recently operated patient groups are all slightly raised (table I, compare with the figure), the present study provides little evidence that a high intake of aluminium through antacids is a risk factor for Alzheimer's disease. On the other hand, the observation period may have been too short, and there is substantial misclassification in our diagnosis and exposure data. Therefore, we cannot rule out the possibility that the mortality from Alzheimer's disease among the regular long term consumers of aluminium containing antacids in our cohort could be considerably raised.
Note added in proof-Broe et al (Neurology 1990;  40: 1698-707) have found no association between antacid use and Alzheimer's disease in the most powerful case-control study conducted to date. Thus the cumulative results from casecontrol studies2-22 give little evidence that antacids are a strong risk factor for Alzheimer's disease.
